Core Insights - Curis, Inc. is set to present clinical data on emavusertib (CA-4948), an IRAK4 inhibitor, at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) from November 19-23, 2025 [1] Group 1: Clinical Data Presentations - The company will showcase three presentations on emavusertib and BTKi clinical data in Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL) [1] - A poster presentation on November 21, 2025, will feature Dr. Christian Grommes discussing the genetic mutation profile and CNS pharmacokinetics in relapsed/refractory PCNSL patients responding to emavusertib and BTKi combination [1] - Another poster presentation on the same day will be led by Dr. Lakshmi Nayak, focusing on the preliminary safety and efficacy of emavusertib in combination with Ibrutinib in relapsed/refractory PCNSL patients [1] Group 2: Presentation Formats and Details - The presentations will include both poster and rapid oral formats, with the rapid oral presentation scheduled for November 22, 2025, by Dr. Christian Grommes [1] - The rapid oral presentation will also analyze the genetic mutation profile and CNS pharmacokinetics in the same patient group [1]

Core Viewpoint - Curis, Inc. is set to report its second quarter 2025 financial and operational results on August 5, 2025, with a conference call scheduled for the same day [1]. Company Overview - Curis, Inc. is a biotechnology company focused on developing emavusertib (CA-4948), an orally available small molecule IRAK4 inhibitor [3]. - Emavusertib is currently being evaluated in multiple clinical studies, including the TakeAim Lymphoma Phase 1/2 study for patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and the TakeAim Leukemia Phase 1/2 study for patients with relapsed/refractory acute myeloid leukemia (AML) [3]. - The drug has received Orphan Drug Designation from the U.S. FDA for the treatment of PCNSL, AML, and myelodysplastic syndrome (MDS) [3]. - Curis holds exclusive licensing rights to emavusertib through a collaboration with Aurigene established in 2015 [3]. - The company has licensed its rights to Erivedge® to Genentech, which is commercializing the drug for advanced basal cell carcinoma [3].